NCT02480998View on ClinicalTrials.gov

Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Influenza, Human
Interventions
BIOLOGICAL

IL-YANG Flu Vaccine QIV 0.5mL

BIOLOGICAL

IL-YANG Flu Vaccine TIV 0.5mL

All Listed Sponsors
lead

Il-Yang Pharm. Co., Ltd.

INDUSTRY

NCT02480998 - Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults | Biotech Hunter | Biotech Hunter